GEN3017

P1/2, N=9, Terminated, Genmab | N=240 --> 9 | Trial completion date: Dec 2032 --> Feb 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2029 --> Feb 2025; Genmab discontinued GEN3017 program following a strategic re-evaluation of Genmab's portfolio.

P1/2, N=240, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting

P1/2, N=240, Recruiting, Genmab | Trial completion date: Jun 2028 --> Dec 2032

P1/2, N=240, Recruiting, Genmab | Not yet recruiting --> Recruiting

P1/2, N=240, Not yet recruiting, Genmab

In the last decade, treatment regimen including brentuximab vedotin have significantly improved prognosis for patients with CD30-expressing lymphomas...Here, we report preclinical data for the novel DuoBody®-CD3xCD30 (GEN3017), a CD3 bsAb targeting CD30-expressing tumor cells...CD30-expressing HL (L428) and ALCL (KI-JK) tumor cell lines were incubated with purified healthy donor T cells (E:T ratio = 4:1) and DuoBody-CD3xCD30 or bsIgG1-CD3xctrl for 72 hours. T-cell mediated cytotoxicity was measured by flow cytometry and expressed as the percentage viable tumor cells normalized to an untreated control sample.